TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15517668
Drug: Tolterodine tartrate
Normalized name: Tolterodine Tartrate
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolterodine tartrate 4 mg (2 mg bid)
Study: 2967624
Drug: Control solutions
Normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solutions of oxygenated Ringer's lactate and nonoxygenated FDA-20
Study: 17964396
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate 4%-sodium hyaluronate 3% (Viscoat) in combination with sodium hyaluronate 1% (Provisc)
Study: 15140340
Drug: Testosterone buccal
Normalized name: testosterone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone buccal system (Striant), 30 mg twice daily
Study: 15140340
Drug: Transdermal gel
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal gel delivery system (T‐gel), AndroGel 5 g containing 1% (50 mg) T, daily for 14 days
Study: 15140340
Drug: Testosterone buccal
Normalized name: testosterone Buccal Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone buccal system
Study: 15140340
Drug: Transdermal gel
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal gel delivery system (T‐gel)
Study: 7649646
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment from an inactive machine
Study: 2502843
Drug: Deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl (10 mg/day)
Study: 30552041
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg dermal patch)
Study: 30552041
Drug: Atomoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (60 mg per os)
Study: 27146248
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of lipid-based nutrient supplements plus malaria and diarrhoea treatment from age 9 to 18 months
Study: 27146248
Drug: Provision of
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provision of lipid-based nutrient supplements plus malaria and diarrhoea treatment
Study: 26088659
Drug: Atomoxetine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine alone or with a stimulant
Study: 26088659
Drug: Antipsychotic usually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic usually together with a stimulant
Study: 26088659
Drug: Other pharmacotherapy
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other pharmacotherapy
Study: 26088659
Drug: Indicated ADHD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicated ADHD medication
Study: 26088659
Drug: Antipsychotic
Normalized name: ANTIPSYCHOTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic
Study: 22188761
Drug: ARA-enriched oil
Normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA-enriched oil (240 or 720 mg ARA per day)
Study: 19395188
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy (EBRT) plus androgen deprivation therapy
Study: 10905544
Drug: Daily fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily fish meals
Study: 8163889
Drug: 0.2% hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% hydrocortisone and 1.0% lignocaine hydrochloride no-touch aqueous spray
Study: 3098573
Drug: Ritanserin (serotonin-S2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (serotonin-S2 antagonist), administered for five days
Study: 31304380
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (six individual physiotherapy sessions over 6 weeks and high-quality online education)
Study: 29924421
Drug: In vivo
Normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vivo exposure group treatment
Study: 20104528
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (ascorbic acid 120 mg, vitamin E 30 mg, beta‐carotene 6 mg, selenium 100 microg, zinc 20 mg)
Study: 15272923
Drug: Raloxifene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (180 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (R‐Exp)
Study: 15272923
Drug: Clomiphene (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene (150 mg/day orally) plus oestradiol (100 microg/24 h) from days 21 to 30 (Cl‐Exp)
Study: 15272923
Drug: E2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 treatment in Group 2 (30 days) plus R from days 21 to 30 (R‐Exp)
Study: 15272923
Drug: E2 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 treatment in Group 2 (30 days) plus Cl from days 21 to 30 (Cl‐Exp)
Study: 11434469
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser (LPL) therapy
Study: 2898052
Drug: B subunit
Normalized name: Modified Cholera toxin B subunit
DrugBank: Modified Cholera toxin B subunit (DB18557)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B subunit killed whole-cell (BS-WC) vaccine
Study: 2898052
Drug: Killed whole-cell-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole-cell-only (WC) vaccine
Study: 28120485
Drug: Triazolam 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.375 mg (positive control)
Study: 25399551
Drug: Dabrafenib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabrafenib (150 mg twice daily) and trametinib (2 mg once daily)
Study: 29724167
Drug: Vemurafenib (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (960 mg twice daily)
Study: 23234813
Drug: Oral recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral recombinant human PTH(1‐31)NH(2) 5mg once daily for 24 weeks
Study: 23234813
Drug: Open-label subcutaneous
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label subcutaneous teriparatide
Study: 17263088
Drug: Soft drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft drink containing 0.232 g of ginseng and 2 g of ginkgo extract
Study: 10931020
Drug: Continued treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with MPFF
Study: 9283511
Drug: meta‐chlorophenylpiperazine (m‐CPP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: meta‐chlorophenylpiperazine (m‐CPP) (1.0 mg/kg)
Study: 7685921
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination (DRE) and transrectal ultrasonography (TRUS)
Study: 3106458
Drug: Acute hpGRF‐44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hpGRF‐44 iv administration (1 microgram/Kg bw)
Study: 3106458
Drug: Sc administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sc administration of the same dose at 4‐h intervals by a programmable portable pump
Study: 22489255
Drug: Risperidone (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2.0 mg)
Study: 18669979
Drug: ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20 mg/day + fenofibrate 160 mg/day
Study: 18669979
Drug: fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 160 mg/day
Study: 16394908
Drug: Intravenous tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tPA and heparin
Study: 8638025
Drug: Empiric amiodarone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric amiodarone therapy
Study: 8638025
Drug: Type-I antiarrhythmic
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type-I antiarrhythmic drugs
Study: 8638025
Drug: Mixed group
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed group of antiarrhythmic drugs
Study: 31738072
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for AUD, duration: 12 weeks
Study: 24446216
Drug: Fufang Xuelian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fufang Xuelian Burn Ointment (FXBO) plus common burn wound therapy
Study: 24446216
Drug: Common burn
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common burn wound therapy
Study: 8472519
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tablet of ST‐679
Study: 8472519
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg capsule of ST‐679
Study: 31926340
Drug: Apremilast 40
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 40 mg
Study: 31926340
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg and 40 mg
Study: 22757665
Drug: 1540 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1540 nm non-ablative fractional laser (NAFL) treatment, 4 treatments at monthly intervals
Study: 22757665
Drug: 1540 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1540 nm non-ablative fractional laser (NAFL) treatment
Study: 21576636
Drug: sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib (400 mg orally twice a day) plus erlotinib (150 mg orally daily)
Study: 21576636
Drug: placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo plus erlotinib (150 mg orally daily)
Study: 10711927
Drug: Ondansetron (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (24 mg daily)
Study: 15321287
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine patient‐controlled analgesia (PCA)
Study: 15321287
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine and Intravenous morphine patient‐controlled analgesia (PCA)
Study: 3899048
Drug: Clomipramine hydrochloride
Normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine hydrochloride (mean dosage, 141 mg/day)
Study: 29790278
Drug: Split-dose 4-L
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split-dose 4-L polyethylene glycol (4-SD)
Study: 29790278
Drug: Routine, morning-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine, morning-only 2-L polyethylene glycol (2-MO)
Study: 14766688
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate 1 g
Study: 3110248
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP), 200 micrograms twice daily
Study: 3110248
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG), 2 mg four times daily
Study: 3110248
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (BDP and SCG)
Study: 27242121
Drug: 30mg zinc
Normalized name: zinc citrate 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mg zinc sulphate dispersible tablet, once daily for six months
Study: 27242121
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for six months
Study: 20592230
Drug: PHMB-preserved solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHMB-preserved solution
Study: 16644196
Drug: Hochu-ekki-to (HET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hochu-ekki-to (HET) 7.5 g/day for two weeks
Study: 16644196
Drug: Placebo (indistinguishable)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (indistinguishable) 7.5 g/day for two weeks
Study: 16249679
Drug: Combined spinal‐epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal‐epidural technique with 27‐gauge Whitacre needle dural puncture without subarachnoid drug administration
Study: 10667430
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months combined androgen blockade therapy (n = 18)
Study: 10667430
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months combined androgen blockade therapy (n = 22)
Study: 1858189
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg administered as an enema
Study: 6136287
Drug: Inert medication
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert medication (Control)
Study: 27986742
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment for 6 weeks
Study: 23755902
Drug: Buffered saline
Normalized name: Phosphate Buffered Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered saline solution (in vitro)
Study: 14763497
Drug: Qb above
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qb above 250 ml/min
Study: 14763497
Drug: Increased Qd
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased Qd from 500 to 800 ml/min
Study: 8404176
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 0.125 mg
Study: 8404176
Drug: Inhaled terbutaline
Normalized name: terbutaline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled terbutaline 1.5 mg
Study: 3492486
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg twice daily for ten days)
Study: 3492486
Drug: Co-trimoxazole (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (160 mg trimethoprim and 800 mg sulphamethoxazole twice daily for ten days)
Study: 21540741
Drug: GW842166 800
Normalized name: GW842166
DrugBank: GW842166 (DB11903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW842166 800 mg
Study: 21540741
Drug: GW842166 100
Normalized name: GW842166
DrugBank: GW842166 (DB11903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW842166 100 mg
Study: 18510961
Drug: Flavanol-rich cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich cocoa (321 mg flavanols per dose)
Study: 18510961
Drug: Nutrient-matched control
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient-matched control (25 mg flavanols per dose)
Study: 18510961
Drug: Flavanol-rich cocoa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanol-rich cocoa (single acute dose)
Study: 9315986
Drug: Pindolol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 7.5 mg/day
Study: 8447613
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine 0.25 mg with adrenaline 200 micrograms (group MA)
Study: 8447613
Drug: Subarachnoid morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid morphine 0.25 mg without adrenaline (group M)
Study: 21189431
Drug: Atorvastatin, 10
Normalized name: Amlodipine Besylate-Atorvastatin, 10 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 10 mg daily for 2 months
Study: 21189431
Drug: Lovastatin, 40
Normalized name: Lovastatin, 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin, 40 mg daily for 2 months
Study: 21189431
Drug: Simvastatin, 20
Normalized name: Simvastatin, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin, 20 mg daily for 2 months
Study: 21189431
Drug: Atorvastatin, Simvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, Simvastatin, Lovastatin
Study: 14961173
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application of Dovobet (calcipotriol 50 micrograms/gram and betamethasone dipropionate 0.5 milligrams/gram)
Study: 14961173
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily application of Dovobet
Study: 10660736
Drug: 5-fluorouracil (5-FU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (5-FU), 300 mg/day
Study: 10660736
Drug: Cyclophosphamide (CPA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (CPA), 150 mg/day
Study: 3085464
Drug: Nifedipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (60 to 90 mg/day)
Study: 23468176
Drug: Etanercept at
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept at 0.4 mg/kg per week for the first year, then 0.4 mg/kg per month for the second year
Study: 21112538
Drug: liposome‐encapsulated 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposome‐encapsulated 2% ropivacaine gel (RL2)
Study: 20542419
Drug: 20% benzocaine
Normalized name: BENZOCAINE 200 mg in 1 g DENTAL GEL [Ipana 20% Benzocaine Topical]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% benzocaine gel (B20)
Study: 21112538
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo gel (P)
Study: 21112538
Drug: liposomal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: liposomal placebo gel (LP)
Study: 11044164
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (nil-by-mouth regimen)
Study: 1859906
Drug: Post-relapse tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-relapse tamoxifen therapy
Study: 1859906
Drug: CMF adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF adjuvant therapy
Study: 6125172
Drug: Propranolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (3 x 40 mg)
Study: 6125172
Drug: Pindolol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (3 x 5 mg)
Study: 6125172
Drug: Both beta‐adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both beta‐adrenoceptor blockers
Study: 31827767
Drug: Non-manipulative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-manipulative therapy
Study: 23867982
Drug: Tamoxifen (TMX)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TMX) 20 mg orally for 3 months
Study: 16967285
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (16 sessions over 2 months)
Study: 16967285
Drug: Pelvic-floor exercises
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic-floor exercises and biofeedback therapy
Study: 15689088
Drug: DTPa HBV-IPV-Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa HBV-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age
Study: 15689088
Drug: DTPa-IPV-Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV-Hib vaccine at 1 1/2, 3 and 5 months of age with separate HBV vaccine at 1 and 5 months of age
Study: 15689088
Drug: DTPa HBV-IPV-Hib
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa HBV-IPV-Hib vaccine
Study: 11694208
Drug: Bupropion SR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion SR, 150 mg/day
Study: 9450160
Drug: Pivagabine (450-900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivagabine (450-900 mg/d by oral route)
Study: 8565166
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs as sole therapy
Study: 7397057
Drug: Brotizolam 0.2
Normalized name: brotizolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.2 mg
Study: 7397057
Drug: Brotizolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.4 mg
Study: 7397057
Drug: Brotizolam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.6 mg
Study: 7397057
Drug: Brotizolam 0.2
Normalized name: brotizolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.2 mg (night)
Study: 7397057
Drug: Brotizolam 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.4 mg (night)
Study: 7397057
Drug: Brotizolam 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.6 mg (night)
Study: 16949180
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplements (30 g/day) for 15 days, initiated at least 3 days before chemotherapy
Study: 16949180
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine supplements (OGS)
Study: 11939925
Drug: i.v. diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. diclofenac 75 mg followed by oral diclofenac 150 mg/day for 3 days
Study: 11939925
Drug: ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 100 mg followed by oral ketoprofen 300 mg/day for 3 days
Study: 28345160
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g l-carnitine + carbohydrate (CARN)
Study: 28345160
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g carbohydrate (CON)
Study: 27256768
Drug: Preoperative bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative bowel preparation with enema
Study: 27256768
Drug: Preoperative bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative bowel preparation with suppository
Study: 22626878
Drug: Routine fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid administration (Group A)
Study: 22626878
Drug: Restricted fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted fluid administration (Group B)
Study: 20889234
Drug: Topical hypericin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hypericin with visible light irradiation (8 to 20 J/cm²), applied twice weekly for 6 weeks